Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A clinical trial testing more potent blood thinners in a high-risk heart group had to be shut down early. The EPIDAURUS trial found that using prasugrel or ticagrelor alongside direct oral anticoagulants (DOACs) in patients with atrial fibrillation and acute coronary syndrome increased bleeding risk without reducing ischemic events. The takeaway: stick with clopidogrel plus a DOAC for this patient population.
A major cardiology trial has delivered a clear warning about using more aggressive antiplatelet therapy in a complex patient group. The EPIDAURUS trial, presented at the European Society of Cardiology Congress and published in Nature Medicine, tested whether swapping clopidogrel for the more potent P2Y12 inhibitors prasugrel or ticagrelor — alongside a direct oral anticoagulant (DOAC) — could better protect patients with both atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing coronary stenting.
The answer was a firm no. The trial was terminated early after safety monitors flagged a significant rise in bleeding events in the experimental group, with no corresponding reduction in ischemic complications like heart attacks or strokes. Of the 1,474 planned participants, only 602 were enrolled before the plug was pulled.
Key Takeaways:
Why it matters: For patients who have both AF and ACS — a combination that demands careful balancing of clot prevention and bleeding risk — this trial confirms that going stronger isn't always better. Clinicians should continue pairing clopidogrel with a DOAC rather than reaching for more potent antiplatelet agents.
